id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-334049-r3rlykli	Lobo-Galo, Naún	FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication	2020-05-14		.txt	text/plain	4132	199	48	Our inclusion criteria for the selection of drugs for potential COVID-19 therapy were: (1) The drug is a FDA-approved that can potentially be repurposed as an ready-to-use therapeutic antiviral; (2) Its use has been extensively studied, and there is sufficient literature on its pharmacology; (3) The drug has few side effects in long-term administration, with not known direct fatalities associated to it, and not additional extensive toxicological studies are needed; (4) Drug can interact with active site of SARS-CoV-2 main protease and reacts with thiol group of its catalytic cysteine, producing an irreversible covalent-inhibition; (5) Administered drug shows efficient distribution through multiple organs, as recent publications suggest the possibility that SARS-CoV-2 has tropism for multiple tissues, beyond the pneumocytes, including heart and blood vessels, liver, intestine, neural cortex and brain stem (Wadman et al., 2020); (6) Drug penetrates the cell membrane, as its antiviral target, the protease acts early during replication in the host cytoplasm; and (7) When administered, drug is metabolized and excreted slowly; and possible metabolites have also potential inhibitory activity.	./cache/cord-334049-r3rlykli.txt	./txt/cord-334049-r3rlykli.txt